Bite-Ev
Leukemia
Beijing GoBroad HospitalEarly Phase 1Active
C
34/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 65/ 100
Competitive context
124 Active assets in the Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE Inhye Ahn | Phase 3 | BB |
PEGASPARGASE Dana-Farber Cancer Institute | Phase 3 | BB |
THIOGUANINE ANHYDROUS Incyte Corporation | Phase 3 | BB |
MERCAPTOPURINE ANHYDROUS Dana-Farber Cancer Institute | Phase 3 | BB |
Cyclophosphamide National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →